LFVN — Lifevantage Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 849146 ·
Last close
$4.78
Market Cap
$60.62M
52W High
$11.62
52W Low
$3.81
ADV30
40,902
Next earnings
2027-02-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 37,117,000 | 27,969,000 | -136,000 | -196,000 | 59,205,000 | 13,726,000 | 25,947,000 |
| Jun 2026 | 42,377,000 | 33,043,000 | 1,667,000 | 1,279,000 | 62,111,000 | 14,920,000 | 28,522,000 |
| Mar 2026 | 43,716,000 | 34,544,000 | 1,678,000 | 1,362,000 | 62,127,000 | 12,483,000 | 28,788,000 |
| Dec 2025 | 48,931,000 | 36,209,000 | 487,000 | 276,000 | 61,169,000 | 10,181,000 | 28,182,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$13,079,000
Investing CF
$-8,115,000
Financing CF
$-4,089,000
CapEx
$-4,372,000
Dividends Paid
$-2,401,000
Buybacks
$-1,935,000
EPS Diluted TTM
$0.21
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-104,286,000
Inventory
$14,228,000
Receivables
$2,739,000
ST Investments
—
EBIT TTM
$3,696,000
Pretax Income TTM
$3,641,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$172,142,000
EBITDA
$7,189,000
Free Cash Flow
$13,403,375
Enterprise Value
$58,708,640
Total Cash
$13,726,000
Total Debt
$9,404,000
Shares Out
12,682,221
Trailing EPS
$0.21
Book Value
$2.64
ROE
8.2%
ROA
4.4%
Div Yield
4.02%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 182,586,000 | 6,100,000 | 5,072,000 | 62,111,000 | 28,522,000 | 33,589,000 | 10,241,000 |
| Jun 2025 | 228,530,000 | 12,199,000 | 9,805,000 | 71,958,000 | 37,317,000 | 34,641,000 | 11,878,000 |
| Jun 2024 | 200,164,000 | 4,332,000 | 2,937,000 | 60,299,000 | 34,308,000 | 25,991,000 | 12,197,000 |
| Jun 2023 | 213,398,000 | 4,259,000 | 2,540,000 | 66,123,000 | 31,474,000 | 34,649,000 | 6,828,000 |
| Jun 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$182,586,000
NetIncome TTM
$5,072,000
OpCashFlow TTM
—
Assets (Latest)
$62,127,000
Forward EPS
$0.24
Max Pain — expiry 2029-01-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $4.81 · call volume: 0 · put volume: 140Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KZIA | KAZIA THERAPEUTICS LTD | $60.68M | $5.31 | — |
| FBIO | Fortress Biotech, Inc. | $60.70M | $1.82 | — |
| ACRV | Acrivon Therapeutics, Inc. | $61.28M | $1.43 | — |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $62.03M | $3.01 | — |
| CTOR | CITIUS ONCOLOGY, INC. | $57.91M | $0.55 | — |
News headlines (Yahoo Finance, 1h cache)
Lifevantage Corp (LFVN) (Q1 2027) Earnings Call Highlights: Revenue Slides 22% as Strategic ...
2026-11-10 07:09 · Yahoo
LifeVantage Corporation Q1 2027 Earnings Call Summary
2026-11-10 02:04 · Yahoo
LifeVantage (LFVN) Q1 2027 Earnings Call Transcript
2026-11-10 01:00 · Yahoo
What Lifevantage (LFVN) Said on Its Q1 Earnings Call
2026-11-09 23:14 · Yahoo
Lifevantage: Fiscal Q1 Earnings Snapshot
2026-11-09 21:53 · Yahoo
LifeVantage Announces Financial Results for the First Quarter Fiscal 2027
2026-11-09 21:05 · Yahoo
New LifeVantage Research Explores How Protandim® Nrf2 Supports Cellular Defense Against Five Modern Environmental Toxins*
2026-10-29 20:05 · Yahoo
LifeVantage to Announce First Quarter Fiscal Year 2027 Results on November 9, 2026
2026-10-26 20:05 · Yahoo
LifeVantage Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-12 20:05 · Yahoo
LifeVantage Unveils Turnaround Plan to Rebuild Brand, Margins and Growth
2026-09-24 07:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.